Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 11 (27), 4210-4

Effect of Itopride, a New Prokinetic, in Patients With Mild GERD: A Pilot Study

Affiliations
Clinical Trial

Effect of Itopride, a New Prokinetic, in Patients With Mild GERD: A Pilot Study

Yong Sung Kim et al. World J Gastroenterol.

Abstract

Aim: Itopride is a newly developed prokinetic agent, which enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions. The importance of esophageal motor dysfunction in the pathogenesis of gastro-esophageal reflux disease (GERD) makes it interesting to examine the effect of itopride on esophageal acid exposure.

Methods: The effect of itopride on esophageal acid reflux variables for 24 h was studied in 26 patients with GERD symptoms, pre-entry total acid exposure time (pH<4) of more than 5% and mild esophagitis (Savary-Miller grades I, II) proven by endoscopy. Ambulatory 24-h pH-metry and symptom assessment were performed after treatments with 150 or 300 mg itopride thrice a day (t.i.d.) for 30 d in random order, using an open label method. For evaluating the safety of itopride, blood biochemical laboratory test was performed and the serum prolactin level was also examined before and after treatment.

Results: Total symptom score was significantly decreased after treatment in 150- or 300-mg group. Itopride 300 mg was significantly effective than 150 mg on decreasing the total per cent time with pH<4, total time with pH<4 and DeMeester score. No serious adverse effects were observed with administration of itopride in both groups.

Conclusion: Itopride 100 mg t.i.d. is effective on decreasing pathologic reflux in patient with GERD and therefore it has the potential to be effective in the treatment of this disease.

Figures

Figure 1
Figure 1
A: Change in mean heartburn score after treatment of itopride. The heartburn score of patients with GERD was improved in both groups of itopride significantly. bP < 0.0001, 1P = 0.0006 vs pretreatment by paired t-test; B: Change in mean total symptom score after treatment of itopride. The mean total symptom score of patients with GERD was improved in both groups of itopride significantly. dP < 0.0001 vs pretreatment by paired t-test.
Figure 2
Figure 2
Change in mean number of acid refluxes after itopride treatment. Mean number of acid refluxes was significantly improved in 300-mg group. 1P = 0.057 vs pretreatment by Wilcoxon’s signed rank test.
Figure 3
Figure 3
Change in mean level of prolactin after itopride treatment. The level of prolactin was not changed after treatment of itopride in GERD.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

Publication types

Feedback